Haemophilia A - KOL Insight

From the dominance of Roche's Hemlibra, the promising rise of Sanofi's Altuviiio, and the potential of gene therapies like BioMarin's Roctavian, uncover the strategic trends driving the future of haemophilia A management. This report offers an in-depth analysis of the evolving therapeutic landscape, highlighting key opportunities and challenges in advancing haemophilia A treatment. Examine the strategic implications of these developments on drug development, market dynamics, and patient care strategies, offering a forward-looking perspective on the haemophilia A landscape.

Key brands covered in this report:

Key questions answered:

• Which drugs constitute the first- and subsequent-line treatments of choice for haemophilia A, and which product attributes contribute to this preference?
• How is the product perceived by the medical community in terms of efficacy, tolerability, ease of administration and other attributes, and how does it compare with other current and pipeline treatment options?
• What do pipeline therapies for haemophilia A need to show in order to become the treatment of choice in a specific line of therapy, and is it likely these products will meet these requirements?
• How will the use of each current and pipeline haemophilia A product change in the future in terms of patient segment, line of therapy and preference?
• What will pipeline products for haemophilia A need to show in terms of efficacy and tolerability endpoints to compete effectively, and what is the likelihood that they will achieve those endpoints?
• Which pipeline products are the most promising and how will they impact current players in the market?
• How will the treatment landscape for haemophilia A evolve in the future for each line of therapy?